Navigation Links
Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego

A group of researchers led by Dr. Adam Godzik at the Burnham Institute for Medical Research is creating tools to speed up the understanding of information gathered// from the human genome project. Rich with $2.1 million funding available to them over a three year period, this consortium, under the name Joint Center for Molecular Modeling, will seek to provide adequate support to scientists from Burnham and UCSD's Computer Science and Engineering department as they team up to develop innovative software.

Researchers are sequencing millions of genes per year in different genomic projects. Solving the structures of the protein products of these genes proceeds at a slower pace of between 3,000 and 5,000 per year. Using the structures of proteins that have already been solved, Dr. Godzik and co-principal investigators Drs. Pavel Pevzner, Yuzhen Ye and Piotr Cieplak will develop novel ways to extract rules and trends of how structures change and evolve. They will use these tools to predict how, for instance, a human protein would differ from its counterpart in mice or bacteria.

"Protein structures can be solved experimentally in a couple of months, sometimes weeks," said Dr. Godzik. "Scientists around the world have already solved tens of thousands of them. Structures of many proteins can also be predicted on a computer in a matter of minutes, but the quality of such models is generally so poor that they are not useful in many applications, such as drug design. We have developed tools that allow us to learn from structures already solved and apply that knowledge to improve predicted structures of new proteins. This funding from the National Institutes of Health makes it possible for us to prove our concept and make our tools available to scientists worldwide."

"Dr. Godzik brings together an interdisciplinary team with an impressive track record," said Dr. Jerry Li, Program Director of the National Institute of General Medical Sciences a
'"/>




Page: 1 2

Related medicine news :

1. New Treatment For Hip Joints
2. Joint replacement surgery outcomes may be affected by obesity and diabetes
3. New combined therapy for Knee Joint pain
4. New Hereditary Bone Joint Disorder Identified
5. Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief
6. A Joint Venture by Golfers And Military Forces To Combat AIDS
7. Asian Nations To Take Joint Efforts Against H5N1
8. Japanese-Indonesian Joint Venture To Produce Bird Flu Vaccine For Farm Animals
9. Increase in the Demand for Artificial Joints
10. Joint Effort among Various Nations to Tackle Bird Flu
11. Joint Research by IIT-K and GSVM
Post Your Comments:
(Date:7/25/2008)...e/ -- Klafter & Olsen LLP has filed a,class action...re" or the,"Company") (Nasdaq: ARTC ) and certain...e Western District of Texas on behalf of all perso...roCare from January 24, 2008,through July 18, 2008...ll,persons or entities who purchased call options ...
(Date:7/25/2008)...iretroviral therapy may be due to genetic factors ...A new study challenges the long-held belief that t...em,s ability to restore itself after HIV patients ...apy (HAART). , From 50 percent to 90 percent of...V. Intravenous drug use is the main cause of both ...
(Date:7/25/2008)...- BeaconEquity.com announces the,availability of T...rs can view all of the daily trading notes for fre...,s Trade Alerts include: DUSA Pharmaceuticals Inc..... (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), A...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
(Date:7/25/2008)...gnificant Improvements in Members, Health, ATLANT...er in health,care quality management solutions for...s entered into a long-term agreement with Wellmark...tion on Quality(SM) Incent and,Reward Best Practic...d,primary care clinicians to promote improved qual...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
...Radiologists are enabled to get more detailed imag...advances made in CT scanners, which also serves to... undergo. // Back in 1987, patients had to undergo...table angiograms before going for a bypass surgery...
...Newer antibiotics like cephalosporins will replace...ing ailments like strep throat, as they are seen t...atment given to // 11,426 children, showed that ev...s more effective than the traditional 10-day dose ...
...A new research has revealed that happiness results...hological Bulletin of the American Psychological A...tributes towards // reinforcing positive emotions,...ake new goals and succeed at them. Dr. Sonja Lyu...
...People in general tend to get the blues during the...they recover soon enough. It is far more difficult..., and the people who suffer // from it require hel..., sleep a lot, and tend to put on weight. They exp...
Other Medicine News:Health News:Penicillin To Pave Way For New Antibiotics 2Health News:Happiness Plays An Important Role In Success 2
(Date:7/23/2008)...ewswire/ -- The following was,released by the U.S....g Member Smith, and Members of the Committee.,Than...e I appeared before this Committee almost six mont...the talented and dedicated professionals,at the Ju...have come to,appreciate that much more deeply thei...
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Study finds recent trend of growing US disparities in health not inevitable 12680 1Study finds recent trend of growing US disparities in health not inevitable 12680 2Study finds recent trend of growing US disparities in health not inevitable 12680 3Krill discovered living in the Antarctic abyss 2314 1Krill discovered living in the Antarctic abyss 2314 2Pharsight to Present at eClinical Forum 12678 1Pharsight to Present at eClinical Forum 12678 2HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 1HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 2HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 3HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 4HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 5HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 6HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 7HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 8HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 9HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 10HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 11HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 12HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 13HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 14HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 15HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 16HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 17HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 18HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 19HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 20HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 21HealthSouth Reports Results for Fourth Quarter Ended December 31 2007 12674 22
...nspire,Pharmaceuticals, Inc. (NASDAQ: ISPH) today ...al trial comparing epinastine nasal,spray and plac...or,the primary endpoint of improvement in total na...ved in the trial, with the higher,dose (0.1%) achi...ty L. Shaffer, Ph.D., Inspire,s President and CEO,...
...tCall/ -- ISTA,Pharmaceuticals, Inc., today announ....S. Phase II/III clinical study of bepotastine for...dy evaluated two,concentrations of bepotastine, ea...ndpoints of the study were the assessment of,effic... redness.,The preliminary results of the study dem...
Other Medicine Technology:Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 2ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 3ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 4ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine 5
Angled for temporal approach. Solid 14 mm blades. Dull finish.
Solid 8 mm blades. Dull finish. Most popular size or model.
Closed wire 5 mm blade with a wing tip twist giving the surgeon better on-axis accessibility.
Angled for temporal approach. Wire 14 mm rounded blades for patient comfort. Dull finish.
Medicine Products: